# Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis

> **NCT04769908** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 40 (estimated)

## Conditions studied

- ICC

## Interventions

- **DRUG:** Systemic Chemotherapy
- **DRUG:** Lenvatinib
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT04769908
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-23
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04769908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04769908, "Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04769908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*